[1]《2012年中国卫生统计年鉴》 [2]曹磊等.结肠直肠癌的临床研究进展[J].临床肿瘤学杂志,2005,10(2):214-216. [3]覃金莲等.雷替曲塞对比 5- 氟尿嘧啶一线治疗晚期结直肠癌疗效和不良反应的 Meta 分析[J] .中国现代医学杂志,2013,23(14):84-90. [4]陈建林等.雷替曲塞治疗晚期结直肠癌临床疗效的 Meta 分析[J]. 中国新药与临床杂志,2010,29(11):853-858. [5]Maughan T S, James R D, Kerr D J, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial[J]. The Lancet, 2002, 359(9317): 1555-1563. [6] Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leuco-vorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 2008;44:2204-11. [7] D?az R, Aparicio J, Giron?s R, et al. Analysis of prognostic factors and applicability of K?hne''s prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy[J]. Clinical colorectal cancer, 2005, 5(3): 197-202. [8]Gravalos C, Garcia-Giron C, Salud A, et al. TOMOX compared to FOLFOX 4 asfirst-line treatment in patients with advanced colorectal cancer (ACRC): results of a multicenter randomised phase II trial. ASCO Annual Meeting Proceedings.J ClinOncol2005; 23(June 1 Supplement); Abstract 3563. [9]Scheithauer W, Kornek G V, Schuell B, et al. Second-line treatment with oxaliplatin raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy[J]. Annals of oncology, 2001, 12(5): 709-714. [10] LAUDANI A, GEBBIA V, LEONARDI V, et al. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma[J]. Anticancer research, 2004, 24(2C): 1139-1142. [11]Carnaghi C, Rimassa L, Garassino I, et al. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer[J]. Annals of oncology, 2002, 13(9): 1424-1429. [12]Feliu J, Salud A, Escudero P, et al. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study[J]. British journal of cancer, 2004, 90(8): 1502-1507. [13]Wilson K S, Fitzgerald C A, Barnett J B, et al. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience[J]. Cancer investigation, 2007, 25(8): 711-714. [14]Ng M, Cunningham D, Norman A R. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)[J]. European Journal of Cancer, 2005, 41(11): 1542-1546. [15]Meydan N, Kundak I, Yavuzsen T, et al. Cardiotoxicity of de Gramont''s regimen: incidence, clinical characteristics and long-term follow-up[J]. Japanese journal of clinical oncology, 2005, 35(5): 265-270. [16] Nutting C, Folkes A. The use of raltitrexed (Tomudex) in a patient with 5-FU induced myocardial ischaemia. J Clin Oncol 1999; 11:66. [17]K? C H. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity[J]. British journal of cancer, 1998, 77(6): 973. [18]庄志祥等. 雷替曲塞与 5 氟尿嘧啶联合奥沙利铂治疗晚期结直肠癌的疗效比较[J].苏州大学学报 (医学版) ,2010; 30( 3):573-578. [19]王佳蕾等,雷替曲塞或氟尿嘧啶 /亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验[J].临床肿瘤学杂志,2012 ,17 (1),6-11. [20]Borget I, Auperin A, Pignon J P, et al. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer[J]. Oncology, 2007, 71(1-2): 40-48. [21] Vorobyov P, Sura M, Avxentieva M, et al. PCN6 ECONOMICAL EVALUATION OF RALTITREXED VERSUS FLUOROURACIL PLUS LEUCOVORIN (5-FU LV) FOR TREATMENT OF ADVANCED COLORECTAL CANCER[J]. Value in Health, 2002, 5(6): 538. [22]Groener MGH, Van Ineveld BM, Byttebier G, et al. An econom ic evaluation of Tomudex (raltitrexed) in metastatic colorectal cancer. and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999; 10: 283-8
|